[{"address1": "One Amgen Center Drive", "city": "Thousand Oaks", "state": "CA", "zip": "91320-1799", "country": "United States", "phone": "805 447 1000", "fax": "805 447 1010", "website": "https://www.amgen.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Beh\u00e7et's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.", "fullTimeEmployees": 26700, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert A. Bradway", "age": 60, "title": "Chairman, CEO & President", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 6731433, "exercisedValue": 0, "unexercisedValue": 64735872}, {"maxAge": 1, "name": "Mr. Peter H. Griffith", "age": 64, "title": "Executive VP & CFO", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 3069385, "exercisedValue": 0, "unexercisedValue": 1429055}, {"maxAge": 1, "name": "Mr. Esteban  Santos", "age": 55, "title": "Executive Vice President of Operations", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 3006074, "exercisedValue": 0, "unexercisedValue": 12988893}, {"maxAge": 1, "name": "Dr. David M. Reese M.D.", "age": 60, "title": "Executive VP & CTO", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 3402742, "exercisedValue": 0, "unexercisedValue": 9008793}, {"maxAge": 1, "name": "Mr. Murdo  Gordon", "age": 56, "title": "Executive Vice President of Global Commercial Operations", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 3243134, "exercisedValue": 0, "unexercisedValue": 5928890}, {"maxAge": 1, "name": "Mr. Matthew C. Busch", "age": 49, "title": "Chief Accounting Officer & VP of Finance", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mike  Zahigian", "title": "Senior VP & Chief Information Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James E. Bradner M.D.", "age": 51, "title": "Executive VP of Research & Development and Chief Scientific Officer", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Justin G. Claeys", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jonathan P. Graham", "age": 62, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 2440307, "exercisedValue": 0, "unexercisedValue": 2105468}], "auditRisk": 2, "boardRisk": 8, "compensationRisk": 2, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 330.15, "open": 330.46, "dayLow": 328.39, "dayHigh": 335.9, "regularMarketPreviousClose": 330.15, "regularMarketOpen": 330.46, "regularMarketDayLow": 328.39, "regularMarketDayHigh": 335.9, "dividendRate": 9.0, "dividendYield": 0.0273, "exDividendDate": 1715817600, "payoutRatio": 1.2343, "fiveYearAvgDividendYield": 2.96, "beta": 0.58, "trailingPE": 47.75143, "forwardPE": 16.329264, "volume": 939465, "regularMarketVolume": 939465, "averageVolume": 2514990, "averageVolume10days": 1693200, "averageDailyVolume10Day": 1693200, "bid": 334.0, "ask": 334.68, "bidSize": 100, "askSize": 100, "marketCap": 179308773376, "fiftyTwoWeekLow": 227.4, "fiftyTwoWeekHigh": 335.9, "priceToSalesTrailing12Months": 6.071677, "fiftyDayAverage": 309.1562, "twoHundredDayAverage": 287.5421, "trailingAnnualDividendRate": 8.64, "trailingAnnualDividendYield": 0.026169924, "currency": "USD", "enterpriseValue": 231415906304, "profitMargins": 0.12742, "floatShares": 534948768, "sharesOutstanding": 536435008, "sharesShort": 8984675, "sharesShortPriorMonth": 9048349, "sharesShortPreviousMonthDate": 1717113600, "dateShortInterest": 1719532800, "sharesPercentSharesOut": 0.0167, "heldPercentInsiders": 0.00248, "heldPercentInstitutions": 0.81154, "shortRatio": 3.44, "shortPercentOfFloat": 0.0168, "bookValue": 9.362, "priceToBook": 35.703907, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": 3763000064, "trailingEps": 7.0, "forwardEps": 20.47, "pegRatio": 3.1, "lastSplitFactor": "2:1", "lastSplitDate": 943228800, "enterpriseToRevenue": 7.836, "enterpriseToEbitda": 19.85, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "AMGN", "underlyingSymbol": "AMGN", "shortName": "Amgen Inc.", "longName": "Amgen Inc.", "firstTradeDateEpochUtc": 424704600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9376b97e-b428-3231-ba0b-142b20481cb4", "gmtOffSetMilliseconds": -14400000, "currentPrice": 334.26, "targetHighPrice": 380.0, "targetLowPrice": 170.0, "targetMeanPrice": 319.72, "targetMedianPrice": 332.0, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 23, "totalCash": 9708000256, "totalCashPerShare": 18.097, "ebitda": 11658000384, "totalDebt": 64020000768, "quickRatio": 0.836, "currentRatio": 1.422, "totalRevenue": 29532000256, "debtToEquity": 1274.791, "revenuePerShare": 55.148, "returnOnAssets": 0.04876, "returnOnEquity": 0.72574997, "freeCashflow": 3753499904, "operatingCashflow": 8096000000, "revenueGrowth": 0.22, "grossMargins": 0.66494006, "ebitdaMargins": 0.39476, "operatingMargins": 0.13334, "financialCurrency": "USD", "trailingPegRatio": 2.4979, "__fetch_time": "2024-07-16"}]